CITIUS PHARMS
PharmaCITIUS PHARMS is a pharmaceutical company focused on Oncology.
CITIUS PHARMS's Key Drugs
CITIUS PHARMS's core commercial portfolio centers on LYMPHIR, spanning Oncology — its most strategically important drugs approved in the last 15 years.
CITIUS PHARMS's Recent FDA Approvals
CITIUS PHARMS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
CITIUS PHARMS's Therapeutic Areas
CITIUS PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CITIUS PHARMS's Top Competitors
CITIUS PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CITIUS PHARMS Pipeline Snapshot
Active clinical trials for CITIUS PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LYMPHIR leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (1)
Company Info
- First Approval
- 2011-06-13
- Latest
- 2024-08-07
- Applications
- 2